Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensartinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Betta Pharmaceuticals Co Ltd

    • Most Recent Events

    • 15 Aug 2023 Status changed from recruiting to completed.
    • 13 Sep 2022 Results (n=482) of a Pop PK model development analysis from four clinical trials: BTP-28311, X396-CLI-101, X396-CLI-301, and BTP-42322 presented at the 47th European Society for Medical Oncology Congress
    • 22 Nov 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top